Cancer Resource--Pathology, Registry and Biorepositories

描述(由申请人提供)： 技术和科学知识的快速发展开启了新的 翻译研究中重要发现的机会。作为一名 结果，将组织特征联系起来变得越来越重要 患者的人口统计、病理和临床记录，没有 损害患者的权利和医疗记录的保密性。这 全面的研究方法将在以下方面取得重大进展 肿瘤的病因、进展和预后的多学科研究 在西奈山医疗中心。这项建议的总体目标是 建立与人类进行癌症研究的基础设施 标本。“癌症资源：病理学、注册和生物信息库” 这里将建立在我们现有的结肠癌和乳腺癌基础设施上 家庭登记、肿瘤登记和标本库。癌症的目的 资源将促进从基础科学到翻译的研究 研究，以及大规模分子流行病学研究。具体来说， 目标是：1)获得接受手术的患者的术前同意。 对偶发或疑似癌症的外科手术(从乳房和结肠开始 癌症)为DHRCC数据和生物库做出贡献；2)建立 全面的数据库，其中包含来自同意的患者的与 病理、临床和流行病学资料。跟踪状态，由 肿瘤登记处，也将包括在这个数据库中；3)建立 包含来自癌症和高密度脂蛋白的血清、血浆和DNA的生物储存库 风险患者和健康对照，供调查人员使用并提出建议 经咨询委员会核准，包括详细的临床、病理和 关于该人群的流行病学数据。储存库服务(血液 加工、等量处理和储存)将可用于样品库 有资助研究的调查人员；4)建立组织信息库，链接 到病人记录，用新采集的石蜡包埋样本， 并提供组织学服务(切片、免疫组织化学染色 和激光捕获显微解剖)，降低了癌症研究人员的成本。一个 将成立咨询委员会以监督数据的运行和 生物信息库，并征求和审查提案的科学性 计划使用组织和血液样本。此共享资源将 促进正在进行的和未来与癌症病因学相关的研究，标记物 癌症进展和癌症诊断后的预后。是否可以使用 有关患者特征的数据将是 使用肿瘤和正常组织以及其他生物标本的转译研究。

DESCRIPTION (provided by applicant): Rapid advances in technology and scientific knowledge have opened new opportunities for important discoveries in translational research. As a result, it is becoming increasingly important to link tissue characteristics of patients to demographic, pathologic and clinical records, without compromising patients' rights and confidentiality of medical records. This comprehensive approach to research would allow for significant progress in the study of cancer etiology, progression and prognosis from various disciplines at Mount Sinai Medical Center. The overall aim of this proposal is to establish the infrastructure for conducting cancer research with human specimens. The "Cancer Resource: Pathology, Registry, and Biorepository" herein will build upon our existing infrastructure of colon and breast cancer familial registries, Tumor Registry and specimen banks. The aims of the Cancer Resource will facilitate research ranging from basic science to translational research, and to large-scale molecular epidemiologic studies. Specifically, the objectives are: 1) to obtain presurgical consent from patients undergoing surgery for incident or suspected cancer (beginning with breast and colon cancer) to contribute to the DHRCC Data and Biorepository; 2) to establish a comprehensive database with information from consented patients related to pathologic, clinical and epidemiologic data. Follow-up status, conducted by the Tumor Registry, will also be included in this database; 3) to establish a biorepository containing banked serum, plasma and DNA from cancer and high- risk patients and healthy controls for use by investigators with proposals approved by the Advisory Committee, with detailed clinical, pathologic and epidemiologic data available on that population. Repository services (blood processing, aliquoting and storage) will be available for specimen banking for investigators with funded studies; 4) to establish a tissue repository, linked to patient records, with freshly harvested and paraffin-embedded specimens, and to provide histology services (sectioning, immunohistochemical staining and laser capture microdissection) at a reduced cost to cancer researchers. An Advisory Committee will be established to oversee the running of the Data and Biorepositories, and solicit and review the scientific quality of proposals planning to use tissue and blood specimens. This Shared Resource will facilitate ongoing and future studies related to cancer etiology, markers of cancer progression, and prognosis after cancer diagnosis. The availability of data on patient characteristics will be an invaluable resource for translational research using tumor and normal tissue and other biospecimens.